APC Announces Positive Results in Combination Cancer Immunotherapy
(firmenpresse) - APC Announces Positive Results in Combination Cancer Immunotherapy
- Regression of tumors and ongoing immunity are observed in pre-clinical study
- Company to engage CRO in order to accelerate program
VANCOUVER, BRITISH COLUMBIA - September 11, 2014 - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC / Frankfurt: 0E8) is excited to report results from its current round of experiments, that not only reinforce previous evidence of the immunotherapeutic properties of APCs protein modification technology, but hold forth the possibility of synergistic effects with other immunotherapies while heralding the entry of a new and potentially powerful approach in the arsenal of anticancer weaponry.
Over the past year we have demonstrated that APCs technology has the ability to overcome immune tolerance of certain tumors that have evolved mechanisms to evade attack by the bodys immune system. APC has been able to enhance the affinity for target cancer cells of a natural human protein that possesses demonstrable anticancer activity, by modifying the protein chemically in a variety of ways. Indeed, various modifications of the protein, have translated into greater antitumor potency in animal models.
Now, results from combination therapy with checkpoint inhibitors have demonstrated very promising results with the first molecule tested from APCs inventory of modified proteins. In experiments with animal models with tumor implants carried out with APCs academic collaborators, checkpoint inhibitors by themselves only slowed tumor growth, but did not cause tumor regression. By marked contrast, in parallel experiments using a combination of a checkpoint inhibitor with APCs D5 protein modification, the tumors were eradicated. As well, subsequent experiments showed that the animals were immune to rechallenge by the same tumor.
APC plans to rapidly capitalize on these findings by expanding testing of its protein modifications to diverse treatment tumor models (i.e., breast, colon, lung). The Company is currently in negotiations with contract research organizations (CROs) to pursue such additional testing over the next few months, and expects to conclude an agreement shortly.
Alexander (Allen) Krantz, APCs CEO, commented, The implications of this early result are potentially huge for our Company. Our scientists through adroit organic chemical synthetic methods and recombinant DNA technology have designed and generated numerous molecules of diverse structure. Each of these molecules has demonstrated high affinity for target cancer cells with potential anticancer activity. As well, there are numerous possibilities for combining each of these molecules with checkpoint inhibitors and other immunomodulators to achieve synergies that lead to effective and long-lasting treatments of formerly intractable cancers. This combination of factors represents an extraordinary opportunity for our Company.
The context for these experiments is an unprecedented and exciting development in cancer drug research, the robust single agent activity that has been observed with immune checkpoint inhibitors, which are regarded as the next big wave of cancer therapies. In contrast to traditional therapy, by mobilizing a patients immune system, immunotherapies have been durable, rendering many patients cancer-free for years, and have persisted without off-target toxicity.
Unfortunately, the majority of patients do not respond or will have an incomplete response to such checkpoint inhibitors by themselves. It is now established that such immune modulating antibody-based immunotherapies offer more benefit to the patient by being administered in combination with other forms of cancer management or in tandem with other immune modulating molecules. This approach is a basis for APCs current focus and has engendered a massive effort on the part of the pharmaceutical industry to discover such clinically viable drug combinations and bring them to market.
About APC
APC has been applying its Foundation TrinityTM Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics market in the near future. The Companys goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent. To achieve this end, it has been the Companys intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface - both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.
ON BEHALF OF THE BOARD
Alexander (Allen) Krantz
President and Chief Executive Officer
FOR FURTHER INFORMATION PLEASE CONTACT:
Advanced Proteome Therapeutics Corporation
Alexander (Allen) Krantz
President and Chief Executive Officer
Tel: (617) 638-0340
http://www.advancedproteome.com
Scott Young
Investor Relations
Tel: (705) 888-2756
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.
Leseranfragen:
The Foundation Trinity™ Technology: Combining Multiple Anti-Cancer Therapies in a Single Agent for Targeted Delivery to Tumors
Cancer is a complex disease, and for therapies to be maximally effective, they must distinguish between normal and cancerous cells. Combination therapies have been employed to counter the multiple mechanisms that tumors use to evade the immune response and resist the efficacious effects of therapeutics. Despite continuing challenges, useful synergies have been obtained with a combination of individual drugs, and, as a result, a broad range of drug types are now being combined because of the promise and the compelling rationale behind combination therapy. Thus, effective treatment for cancer requires not only the discovery of individual drugs with antitumor activity, but also knowledge of the best way to combine these drugs.
" alt="Ximen Begins Drill Program Today">
" alt="Santacruz Silver Reports PEA Results and New Resource on San Felipe Project, Mexico">
Datum: 11.09.2014 - 15:21 Uhr
Sprache: Deutsch
News-ID 336137
Anzahl Zeichen: 6282
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 234 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"APC Announces Positive Results in Combination Cancer Immunotherapy
"
steht unter der journalistisch-redaktionellen Verantwortung von
Advanced Proteome Therapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
